Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc was a commercial-stage biopharmaceutical company focused on sleep medicine before its acquisition by Alkermes plc. Its company updates centered on LUMRYZ, an FDA-approved sodium oxybate extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Recurring developments included LUMRYZ commercialization, clinical and regulatory disclosures for the REVITALYZ trial in idiopathic hypersomnia, operating and financial results, material agreements, shareholder voting matters, governance items and capital-structure changes tied to its public-company status and completed acquisition.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced a conference call on May 10, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, ending March 31, 2021. The call will provide updates on the company’s progress, particularly focusing on FT218, a sodium oxybate formulation intended for treating narcolepsy symptoms. Investors can join via dial-in or listen to a live webcast from the investor relations section of Avadel's website, with a replay available for 90 days.
Avadel Pharmaceuticals (Nasdaq: AVDL) presented positive secondary endpoint data for FT218 at the 2021 AAN Meeting. The investigational once-nightly formulation of sodium oxybate showed significant improvements at doses of 6 g, 7.5 g, and 9 g in treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. Results demonstrated clinically meaningful enhancements in sleep quality, arousals, and nocturnal sleep disturbances, with a PDUFA target action date set for October 15, 2021, for FDA review.
Avadel Pharmaceuticals (Nasdaq: AVDL) is set to present new secondary endpoint data from its pivotal REST-ON Phase 3 trial of FT218, a once-nightly sodium oxybate formulation, at the 2021 American Academy of Neurology Annual Meeting from April 17-22. Key poster presentations include polysomnographic measures of sleep continuity and the impact of daytime sleepiness, sleep quality, hallucinations, and sleep paralysis in narcolepsy patients. FT218, aimed at treating excessive daytime sleepiness and cataplexy, received FDA's Orphan Drug Designation and has a PDUFA target date of October 15, 2021.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) will participate in a fireside chat at Stifel's Third Annual CNS Day on March 31 at 3 p.m. ET. The discussion will focus on FT218, an investigational formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. A live webcast will be available for attendees, along with a recording accessible for 90 days on the company’s website.
Avadel Pharmaceuticals (AVDL) announced the FDA's acceptance of its New Drug Application for FT218, aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. The PDUFA target action date is set for October 15, 2021. In preparation for the product launch, key appointments were made in Commercial and Clinical Affairs. The company reported no revenue for Q4 2020, with a net loss of $11.3 million, compared to a loss of $2.7 million in Q4 2019. Cash reserves stand at $221.4 million, indicating ample liquidity for upcoming initiatives.
Avadel Pharmaceuticals (Nasdaq: AVDL) announces a collaboration with the AASM Foundation to support the 2021 Young Investigators Research Forum, providing scholarships and training for 24 early career sleep researchers. This program enhances career development in sleep medicine, offering crucial skills in funding and research processes. Avadel aims to bolster research in sleep health, particularly for conditions like narcolepsy. The initiative reflects Avadel's commitment to advancing sleep medicine and investing in the future of sleep research.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the online publication of four Phase 1 studies regarding FT218, a once-nightly formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. The studies, published in Clinical Therapeutics, demonstrated bioequivalent drug exposure and a favorable pharmacokinetic profile supporting once-nightly dosing. FT218 was previously granted FDA Orphan Drug Designation, and the New Drug Application (NDA) was accepted for filing on February 26, 2021, with a target action date of October 15, 2021.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced the FDA has accepted its New Drug Application (NDA) for FT218, a once-nightly sodium oxybate formulation for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy. The FDA assigned a PDUFA target action date of October 15, 2021. FT218, which received Orphan Drug Designation, may offer clinical advantages over the existing twice-nightly formulation. The NDA is backed by positive results from the Phase 3 REST-ON study, with further data expected at upcoming conferences.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced participation in fireside chats at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021 and the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021. The management team will discuss the company's investigational drug, FT218, a once-nightly formulation of sodium oxybate for treating narcolepsy-related symptoms. Webcasts of these events will be available on the company's website for 90 days following the presentations.
Avadel Pharmaceuticals (Nasdaq: AVDL) will host a conference call on March 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q4 and FY 2020. The company focuses on developing FT218, a once-nightly formulation of sodium oxybate for treating narcolepsy. Investors can access the call at (877) 407-9716 for the U.S. and Canada or (201) 493-6779 internationally, with conference ID 13716363. A live audio webcast will be available on the company’s website, accessible for replay for 90 days post-event.